How to lead a research team from #hackathon to plenary in 6 months
…continue reading the full story in The Cancer Letter and Q&A with Matthew Ong
Feature image credit: The Cancer Letter
Similar Posts
Rising cost of HIV drugs
Digging through the Medicaid Prescription Drug Database, I want to find out if HIV drug prices are rising faster over time compared to other daily medications for chronic diseases. I stratified by the number of drugs in each combination tablet, and next I will need to adjust for inflation. Let me know if you think of…
BBC Interview
On Tuesday, April 17, the journal Nature Scientific Reports published our paper “Projected effectiveness and added value of HIV vaccination campaigns in South Africa: A modeling study.” A few hours later, a reporter from BBC World Service reached out to discuss the the results of our study. Live Interview You can listen to this clip with…
Incentivizing health-promoting behaviors
A new comprehensive landscape analysis of Medicaid health behavior incentive programs gathers together many challenges and potential solutions in the latest issue of Health Affairs. In 2017-2018 the team interviewed 80 key-informant stakeholders and searched the literature. The most common incentive type offered by programs was gift cards or vouchers, including cash, Visa gift cards, specific venue…
Better Health Policy for Successful Live Theater in COVID-19
The best health and economic policies for safe, successful, live theater in 2021-2023 will be dynamic – adapting protocols quickly to new scientific evidence, flexing capacity limits according to vaccination and testing. On Thursday April 1, 2021, the COVID Theatre Think Tank hosted a national town hall for the theatre industry to address the current…
Immunotherapy increasing at end of life
Our new study on the rise of immunotherapy drugs at the end of life with bladder cancer learned from real-world patients by using @flatironhealth curated EHR data. We hypothesized that advanced urothelial cancer patients would increasingly receive checkpoint inhibitors near the end of life, as they tend to have more favorable side effect profiles…
How should we evaluate ACA impact on HIV?
Lipira and colleagues recently published this comprehensive review article framing a research agenda to evaluate the impact of the Affordable Care Act (commonly called the “ACA” or “Obamacare”) on HIV care, outcomes, prevention, and disparities. Lipira and colleagues identified several challenges to comprehensive HIV care that could be remedied with informed programming and policy. First, the ACA does…
